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In this issue of Cell Stem Cell, Min et al. (2008) identify Egr1 as a novel hematopoietic stem cell (HSC) tran-
scription factor that regulates proliferation and mobilization of these cells. An improved understanding of
Egr1 targetsmay lead to better strategies to expand populations of HSCs ex vivo for therapeutic applications.HSCs have been instrumental in the treat-
ment of leukemias and other fatal dis-
eases. However, the availability of bone
marrow donors is limited, and so far it
has not been possible to expand HSCs
ex vivo without losing their unique func-
tional properties. Progress in this matter
has been hindered by our incomplete
understanding of the circumstances that
facilitate self-renewal of HSCs. HSCs are
regulated by complex context-dependent
and developmental-stage-specific mech-
anisms. Distinct regulators dictate the de-
velopment of HSCs in the multiple fetal
hematopoietic sites and in the bone mar-
row. In each location, homeostasis is
maintained by combinations of intrinsic
and microenvironmental cues that bal-
ance the multiple fate options available
to HSCs, such as self-renewal, migration,
differentiation, or death (Figure 1) (Jude
et al., 2008; Teitell and Mikkola, 2006).
The fate of HSCs can also be influenced
by pharmacological agents, such as by
using cyclophosphamide/G-CSF treat-
ment, after which HSCs can be harvested
for therapeutic use. This protocol relies on
the ability to harness the HSC regulatory
machinery that governs their proliferation
and release into circulation while conserv-
ing their capacity for engraftment, self-
renewal, and multilineage differentiation.
Yet, we know very little about the molecu-
lar programs that dictate this process.
To define the cell-intrinsic-regulatory
mechanisms responsible for HSC mobili-
zation, Min et al. compared gene expres-
sion between quiescent HSCs and prolif-
erating, premigratory HSCs isolated from
cyclophosphamide/G-CSF-treated mice302 Cell Stem Cell 2, April 2008 ª2008 Else(Min et al., 2008). Mobilization treatment
resulted in drastic downregulation of the
early response gene Egr1. This zinc-finger
transcription factor has the capacity to act
both as an activator and repressor; how-
ever, its role in regulating HSC function
has been unknown. Analysis of Egr1-defi-
cient mice revealed a significant increase
in the frequency of cycling HSCs. How-
ever, the enhanced proliferation of HSCs
resulted in only a modest increase in their
accumulation in the bone marrow, as as-
sessed by FACS analysis and transplan-
tation. Strikingly, Egr1/ mice exhibit
a 5- to 10-fold larger pool of circulating
HSCs. Importantly, HSCs isolated from
the peripheral blood of Egr1/ animals
retained their function, as evidenced by
robust long-term multilineage engraft-
ment upon transplantation (Figure 1).
Although several other mouse models
exhibit increased HSC cycling, the pheno-
type of Egr1-deficient mice is distinct, in
that stable, functional HSC populations
are evident in both the bone marrow and
peripheral blood. In contrast, in most
models in which HSC quiescence is over-
come, such as following perturbation of
transcription factors (JunB, Mll), signal
transduction pathways (PI3K, via PTEN
and FoxO1/3/4 deletion), cell-cycle ma-
chinery (p21), and the HSC niche (inhibi-
tion of Wnt signaling by Dkk1) (Fleming
et al., 2008; reviewed in Jude et al.,
2008), profound defects in HSC function
are also observed. Indeed, accelerated
proliferation tends to correlate with poor
engraftment of reconstituted cells and/or
premature exhaustion of the HSC pool.
Egr1-deficient HSCs maintain the abilityvier Inc.to reconstitute irradiated hosts for multi-
ple rounds of serial transplantation,
although this capacity is lost eventually.
Furthermore, several mutant mouse
strains, such as JunB, PTEN, or FoxO1/
3/4 knockouts that exhibit increased cy-
cling, ultimately develop myeloprolifera-
tive disease and leukemia, and yet these
pathologies are not observed in Egr1/
mice (Jude et al., 2008).
How do Egr1/ HSCs maintain their
functional properties, and relative homeo-
stasis, despite exhibiting increased prolif-
eration? It is well documented that HSCs
in the adult bone marrow are predomi-
nantly quiescent and that only those that
reside in G0 are able to give rise to long-
term reconstitution when transplanted
(Bowie et al., 2006; Passegue et al.,
2005). In contrast, HSCs proliferate
actively during fetal development and
yet are still able to repopulate the hemato-
poietic system of adult recipients after
transplantation (Bowie et al., 2006). This
relationship between HSC cycling and
function is developmentally timed and
shifts to the adult phenotype 3–4 weeks
after birth in mice (Bowie et al., 2006).
Given that Egr1-deficient HSCs are both
functionally competent and actively prolif-
erating, it would be interesting to deter-
mine when this gene is first expressed in
hematopoiesis. It may be that Egr1 ex-
pression is initiated during the fetal-to-
adult developmental switch. It is tempting
to hypothesize that Egr1/ HSCs may
exhibit other properties in common with
fetal HSCs. However, while CD34 is nor-
mally expressed in fetal HSCs and adult
HSCs activated by 5-FU treatment, both
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Egr1/ mice were CD34, which is the
expected phenotype of quiescent LT-
HSCs in the adult. In this respect, Egr1/
HSCs have neither retained fetal proper-
ties nor exhibited a phenotype related to
HSC activation.
In addition to the cycling properties and
cell surface phenotype differences, fetal
and adult HSCs can be distinguished ac-
cording to the molecular mechanisms
that protect their capacity to self-renew.
For example, fetal HSCs require Sox17,
whereas Sox17 is dispensable in the adult
and is downregulated in bone marrow
HSCs at the time when the fetal-to-adult
switch occurs (Kim et al., 2007). In com-
parison, self-renewal of adult HSCs re-
quires Bmi1, whereas the fetal HSC pool
seems unaffected in Bmi1/ fetuses
(Park et al., 2003). Interestingly, Bmi1
was found to be upregulated in Egr1/
HSCs, raising the question of whether
elevated Bmi1 expression contributes to
the observed ‘‘productive proliferation’’
of HSCs in Egr1/ mice (Figure 1). Taken
together, Egr1/ HSCs seem to share
properties with both fetal and adult
HSCs. To better understand how Egr1-
deficient HSCs exhibit both increased
cycling and sustained expansion and
mobilization of functional HSCs, it will be
important to determine whether the
Egr1/ HSCs that engraft are, in fact, in
cycle when transplanted and whether
circulating HSCs maintain their activated
status while in the blood. To date, no
evidence has demonstrated that HSCs
that divide while in circulation retain their
functional properties. Indeed, even after
cyclophosphamide/G-CSF mobilization,
circulating HSCs return to G0/G1 (Uchida
et al., 1997).
It is generally thought that HSCs be-
come vulnerable if disconnected from
the supportive niche for extended pe-
riods. Accordingly, although HSC migra-
tion to and from the bone marrow is
a physiological phenomenon, the number
of circulating HSCs is typically low, and
their transit time while in the blood is al-
ways short (Wright et al., 2001). Egr1/
HSCs generate a circulating population
of HSCs even when transplanted to wild-
type recipients, verifying that this pheno-
type is not dependent on loss of Egr1 in
the marrow microenvironment and so is
cell autonomous. It is of interest whether
circulating HSCs maintain their function
in the absence of extracellular signals or
whether mobilized cells receive support-
ive cues within the circulation or during
brief environmental contact(s) with bone
marrow or other tissues. The use of para-
biotic mouse models, for example, may
shed light on the dynamics and regulation
of the circulating Egr1/HSC population.
It is widely held that the bone marrow
contains a finite number of HSC niches.
Therefore, does loss of Egr1 lead to HSC
mobilization by default, or is HSC mobili-
zation a secondary effect of the proliferat-
ing HSC pool expanding beyond the num-
ber of available niches in the marrow? To
address this point, the authors assessed
HSC frequencies in knockout mouse
model for p21, a cell-cycle inhibitor that
is downregulated in Egr1/ HSCs. Inter-
estingly, p21/ mice did not harbor a cir-
culating HSC pool, suggesting that prolif-
eration of HSCs does not automatically
result in their mobilization. In the case of
Egr1/ HSCs, none of the well-known
mediators of HSCs migration and homing
(a4 and b1 integrins, SDF1 receptor
CXCR4, and Rac1 and Rac2 GTPases)
were affected, implying that Egr1 may
regulate yet-unidentified molecular pro-
grams that retain quiescent HSCs in their
niche.
It is important to note that, although
Egr1/ HSCs become exhausted earlier
than control cells, this defect occurs only
after prolonged hematopoietic stress dur-
ing serial transplantations. The observa-
tion that large, robust populations of func-
tional HSCs are present in the circulation
of Egr1-deficient animals implies that
transient targeting of Egr1-regulated
pathways may be an attractive strategy
to expand and mobilize HSCs without
challenging their long-term functionality.
Defining these pathways in the context
of cell-cycle regulation and dependence
on niche-delivered signals may therefore
offer new routes to generate clinically rel-
evant numbers of HSCs ex vivo while still
preserving their unique functional proper-
ties and developmental potential.
Figure 1. Loss of Egr1 Switches the Balance among HSC Fate Choices toward Proliferation
and Mobilization
Min et al. (2008) demonstrate that loss of the zinc-finger transcription factor Egr1 results in increased pro-
liferation and mobilization of HSCs. Egr1/ HSCs both in bone marrow and blood were fully functional,
although their life span was slightly shortened. The paper suggests reduced expression of p21 and
increased expression of Bmi1 as one potential mechanism that allows increased cycling of HSCs while
retaining their functionality, whereas yet-unknown mechanisms may be involved in releasing HSCs from
their niche to circulation (TBD, to be determined).Cell Stem Cell 2, April 2008 ª2008 Elsevier Inc. 303
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